From Financial Modeling Prep: 2025-03-24 07:00:00

In the biopharmaceutical industry, Alkermes plc (NASDAQ:ALKS) stands out with a strong ROIC of 22.09% and a high ROIC to WACC ratio of 3.15, indicating efficient capital utilization and superior performance compared to peers like Neurocrine Biosciences, Alnylam Pharmaceuticals, and Nektar Therapeutics. Alkermes’ ability to generate returns above its cost of capital sets it apart in a competitive market.



Read more at Financial Modeling Prep:: Alkermes plc (NASDAQ:ALKS) Outperforms Peers in Ca…